Monitor for actual sales in upcoming days via Form 4 filings; while the volume is small and seller is a long-term institutional holder, any execution could add minor near-term selling pressure. No immediate catalyst or fundamental change implied.
KROS drugs
KROS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 1 $11.69entry
- T+1 · 8mo ago +2.65%α +2.57% · $12.00
- T+5 · 7mo ago +6.84%α +3.08% · $12.49
- T+20 · 7mo ago −5.05%α −14.77% · $11.10
- T+60 · 5mo ago −6.50%α −19.88% · $10.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
OrbiMed Advisors LLC, on behalf of its affiliate OrbiMed Genesis Master Fund, LP, has filed a Form 144 to notify intent to sell up to 45,057 shares of Keros Therapeutics (KROS) common stock. The shares were acquired in connection with KROS's IPO on April 13, 2020, and are now eligible for sale under Rule 144.
Key Facts
- Reporting entity: OrbiMed Advisors LLC, acting for OrbiMed Genesis Master Fund, LP
- Number of shares proposed for sale: 45,057
- Shares acquired: April 13, 2020 (IPO date)
- Filing date: March 31, 2026
- Shares to be sold: Common stock of Keros Therapeutics, Inc. (KROS)
- Broker: Themis Trading LLC
- Market: Nasdaq Stock Market
Financial Impact
Approximately $2.2 million based on current market price (~$49 per share), representing a small fraction of KROS's $218M market cap
Risk Factors
- Potential for increased near-term selling pressure if sale is executed rapidly
- Signal of reduced conviction by a long-standing institutional investor
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0000947871-26-000370 |
| Document: 0000947871-26-000370-index.html | 0000947871-26-000370 |
| Document: 0000947871-26-000370.txt | 0000947871-26-000370 |
Track record
27 reports on KROS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago Press Release Neutral 5/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
- Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers